KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $177.4 million.

  • Recursion Pharmaceuticals' Operating Expenses rose 4254.48% to $177.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $767.3 million, marking a year-over-year increase of 6703.0%. This contributed to the annual value of $537.8 million for FY2024, which is 3628.87% up from last year.
  • Recursion Pharmaceuticals' Operating Expenses amounted to $177.4 million in Q3 2025, which was up 4254.48% from $195.4 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Operating Expenses' 5-year high stood at $206.1 million during Q1 2025, with a 5-year trough of $33.0 million in Q1 2021.
  • For the 5-year period, Recursion Pharmaceuticals' Operating Expenses averaged around $104.7 million, with its median value being $92.7 million (2023).
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 13872.74% in 2021, then soared by 1061.59% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Operating Expenses (Quarter) stood at $67.5 million in 2021, then increased by 10.62% to $74.7 million in 2022, then soared by 47.1% to $109.8 million in 2023, then soared by 71.47% to $188.3 million in 2024, then dropped by 5.81% to $177.4 million in 2025.
  • Its Operating Expenses was $177.4 million in Q3 2025, compared to $195.4 million in Q2 2025 and $206.1 million in Q1 2025.